Cargando…
Advances in limb salvage treatment of osteosarcoma
Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739147/ https://www.ncbi.nlm.nih.gov/pubmed/29296558 http://dx.doi.org/10.1016/j.jbo.2017.11.005 |
_version_ | 1783287814816792576 |
---|---|
author | Yang, Yichun Han, Lei He, Zewei Li, Xiaojuan Yang, Suping Yang, Jifei Zhang, Ya Li, Dongqi Yang, Yihao Yang, Zuozhang |
author_facet | Yang, Yichun Han, Lei He, Zewei Li, Xiaojuan Yang, Suping Yang, Jifei Zhang, Ya Li, Dongqi Yang, Yihao Yang, Zuozhang |
author_sort | Yang, Yichun |
collection | PubMed |
description | Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade. |
format | Online Article Text |
id | pubmed-5739147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-57391472018-01-02 Advances in limb salvage treatment of osteosarcoma Yang, Yichun Han, Lei He, Zewei Li, Xiaojuan Yang, Suping Yang, Jifei Zhang, Ya Li, Dongqi Yang, Yihao Yang, Zuozhang J Bone Oncol Review Article Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade. Elsevier 2017-11-26 /pmc/articles/PMC5739147/ /pubmed/29296558 http://dx.doi.org/10.1016/j.jbo.2017.11.005 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Yang, Yichun Han, Lei He, Zewei Li, Xiaojuan Yang, Suping Yang, Jifei Zhang, Ya Li, Dongqi Yang, Yihao Yang, Zuozhang Advances in limb salvage treatment of osteosarcoma |
title | Advances in limb salvage treatment of osteosarcoma |
title_full | Advances in limb salvage treatment of osteosarcoma |
title_fullStr | Advances in limb salvage treatment of osteosarcoma |
title_full_unstemmed | Advances in limb salvage treatment of osteosarcoma |
title_short | Advances in limb salvage treatment of osteosarcoma |
title_sort | advances in limb salvage treatment of osteosarcoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739147/ https://www.ncbi.nlm.nih.gov/pubmed/29296558 http://dx.doi.org/10.1016/j.jbo.2017.11.005 |
work_keys_str_mv | AT yangyichun advancesinlimbsalvagetreatmentofosteosarcoma AT hanlei advancesinlimbsalvagetreatmentofosteosarcoma AT hezewei advancesinlimbsalvagetreatmentofosteosarcoma AT lixiaojuan advancesinlimbsalvagetreatmentofosteosarcoma AT yangsuping advancesinlimbsalvagetreatmentofosteosarcoma AT yangjifei advancesinlimbsalvagetreatmentofosteosarcoma AT zhangya advancesinlimbsalvagetreatmentofosteosarcoma AT lidongqi advancesinlimbsalvagetreatmentofosteosarcoma AT yangyihao advancesinlimbsalvagetreatmentofosteosarcoma AT yangzuozhang advancesinlimbsalvagetreatmentofosteosarcoma |